Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function

International Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 4, 2002, Pages 150-157

  Seeger, H ^a   Petersen, G ^a   Schulte Wintrop, E ^a   Teichmann, A T ^a   Mueck, A O ^a  

^a Sec Gynecol Endocrinol/Menopause   (Germany)

Author keywords

Oral contraception; Serum values; Urinary excretion; Vasoactive markers

Indexed keywords

BIOCHEMICAL MARKER; CELL ADHESION MOLECULE; CYCLIC GMP; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTREL; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LEIOS; ORAL CONTRACEPTIVE AGENT; PROSTACYCLIN; THROMBOXANE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD SAMPLING; BLOOD VESSEL TONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLITE; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; URINARY EXCRETION; URINE LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0036213458     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40150     Document Type: Article

References (24)

1. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production
2. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
3. Vascular effects of hormones
4. Combined oral contraceptives and cardiovascular disease
5. Homocysteine and endothelial function
6. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women
7. 1α from human urine
8. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
9. Cardiovascular disease and hormone replacement therapy
10. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type II diabetes: The Hoorn study
11. 17β-Estradiol and endothelial nitric oxide synthase
12. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal women
13. A randomized controlled study of the effect of 17β-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women
14. Is there any effect of estradiol on the vasodilating NO/cGMP-system? Investigations of the mechanism of cardiovascular protection by estrogen substitution in postmenopausal women
15. Urinary prostanoids in postmenopausal women after transdermal and oral estrogen
16. Urinary cGMP-excretion after hormone replacement therapy in postmenopausal women
17. Urinary excretion of vasoactive markers following estrogen replacement therapy in postmenopausal women
18. Effect on biochemical vasoactive markers during postmenopausal HRT: Estradiol vs. estradiol/dienogest
19. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men
20. Cardioprotective effects of ovarian hormones and the HERS in perspective
21. Effect of oral contraceptives on the urinary excretion of biochemical markers indicating vasoactive action
22. Effect of sequential estrogen/progestin treatment on biochemical vasoactive markers in postmenopausal women comparing oral and transdermal application
23. Effect of oral contraceptives containing 20 and 35 micrograms ethinylestradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers
24. 2 in humans